Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19
A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 111 participants.
Also called NCT04416048
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 2
- Enrolled
- 111 participants
- Sponsor
- Registry
-
NCT04416048 -
2020-002282-33
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Germany
- Registry status
- Terminated
Technical summary
Registry record NCT04416048. Randomized; no masking; primary purpose prevention. Start 2020-11-30 (actual); primary completion 2021-07-20 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19
- Acronym
- COVID-PREVENT
- Condition
- COVID-19
- Intervention (Drug)
- Rivaroxaban
- Intervention (Other)
- Standard Of Care (SOC)
- Lead sponsor
- Charite University, Berlin, Germany
- Collaborator
- Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)
- Collaborator
- Bayer
Record details
- Record id
cardio:ct-nct04416048- Content hash
28dd16fa86473b420ef2c6ef2644ecde448de484e777aa842044091bb9fc53ea